--- title: "Roche Shareholders Approve All Proposals At 2026 Annual Meeting" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/278577046.md" description: "Roche Holding AG's shareholders approved all proposals at the 2026 Annual General Meeting, with 77.22% of shares voting. Key decisions included the approval of the 2025 financial statements, a dividend increase to 9.80 Swiss francs per share, and the re-election of Severin Schwan as Chairman. Lubomira Rochet was elected to the Board, and changes to the capital structure were authorized. Roche shares are currently trading at $54.10, down 0.46%." datetime: "2026-03-10T14:50:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278577046.md) - [en](https://longbridge.com/en/news/278577046.md) - [zh-HK](https://longbridge.com/zh-HK/news/278577046.md) --- > 支持的语言: [English](https://longbridge.com/en/news/278577046.md) | [繁體中文](https://longbridge.com/zh-HK/news/278577046.md) # Roche Shareholders Approve All Proposals At 2026 Annual Meeting (RTTNews) - Roche Holding AG (RHHBY), a pharmaceutical company, announced on Tuesday, that its shareholders approved all proposals presented by the Board of Directors at the company's 2026 Annual General Meeting. A total of 594 shareholders representing 77.22 percent of the 106,691,000 shares voted to approve the 2025 Annual and Consolidated Financial Statements, as well as the Remuneration and Sustainability reports. Shareholders also re-elected Severin Schwan as Chairman of the Board with 97.75 percent of the votes and approved a dividend increase to 9.80 Swiss francs per share, marking the company's 39th consecutive dividend increase. In addition, shareholders re-elected the existing board members and approved the election of Lubomira Rochet to the Board of Directors. They also approved remuneration plans for the board and executive committee and authorized changes to the company's capital structure, including replacing Genussscheine with Participation Certificates listed on the SIX Swiss Exchange. RHHBY is currently trading at $54.10, down $0.25 or 0.46 percent on the OTC Markets. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### 相关股票 - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-CN/quote/IHI.US.md) - [ROCHE HOLDINGS AG (RHHVF.US)](https://longbridge.com/zh-CN/quote/RHHVF.US.md) - [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-CN/quote/LABD.US.md) - [Roche (RHHBY.US)](https://longbridge.com/zh-CN/quote/RHHBY.US.md) ## 相关资讯与研究 - [Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply | RHHBY Stock News](https://longbridge.com/zh-CN/news/280956832.md) - [FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up](https://longbridge.com/zh-CN/news/281399710.md) - [Roche Announces Launch Of Cobas MPX-E Assay](https://longbridge.com/zh-CN/news/280960336.md) - [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-CN/news/281346305.md) - [BUZZ-Soleno jumps as Nuerocrine strikes $2.9 bln takeover deal](https://longbridge.com/zh-CN/news/281754875.md)